What is BioAtla?
BioAtla is a clinical-stage biopharmaceutical company focused on the discovery and development of novel monoclonal antibody and cell-based therapeutics. Its core innovation lies in the Conditionally Active Biologics (CAB) technology, which allows for the creation of proteins that are active only in the specific conditions of the tumor microenvironment. This selectivity is a critical differentiator in the competitive landscape of oncology, as it potentially enables the treatment of cancers that were previously considered untreatable due to target expression in healthy tissues. Supported by a robust intellectual property portfolio of over 700 patents, the company is well-positioned to disrupt traditional biopharma manufacturing and therapeutic delivery models.
How much funding has BioAtla raised?
BioAtla has raised a total of $547.7M across 9 funding rounds:
Debt
$5.8M
Private Equity
$39M
Series C
$45M
Series B
$84M
Series A
$37M
Multiple Rounds
$261.9M
Share Placement
$75M
Debt (2014): $5.8M, investors not publicly disclosed
Private Equity (2015): $39M, investors not publicly disclosed
Series C (2016): $45M supported by Global BIO Impact Fund
Series B (2016): $84M, investors not publicly disclosed
Series A (2017): $37M backed by SunTerra Capital, F1 BioVentures LLC, and Sinobioway Group
Debt (2020): $350K with participation from PPP
Series D (2020): $72.5M led by Pfizer Ventures, Boxer Capital, Cormorant Asset Management , LLC, Soleus Capital, HBM Healthcare Investments AG, Pappas Capital, Janus Henderson Investors, and Farallon Capital Management , L.L.C.
Stock Issuance/Offering (2020): $189M, investors not publicly disclosed
Share Placement (2021): $75M featuring Great Point Partners and Deerfield Management
Key Investors in BioAtla
Great Point Partners
A leading health care investment firm that provides growth equity and recapitalization to biopharmaceutical and medical infrastructure companies.
Deerfield Management
An investment firm focused on advancing healthcare through flexible funding models, data-driven intelligence, and support for innovative medical initiatives.
Pfizer Ventures
The venture capital arm of Pfizer Inc., dedicated to discovering and developing breakthrough therapies and vaccines to address significant global health challenges.
What's next for BioAtla?
Looking ahead, BioAtla is poised to leverage its recent capital influx to accelerate its clinical pipeline and refine its manufacturing capabilities. The strategic focus remains on validating the efficacy of its CAB-based candidates in human trials, which will be instrumental in establishing the company as a premier partner for larger pharmaceutical entities. As the firm continues to scale, the integration of its CIAO! platform will likely remain a central pillar of its operational strategy, driving efficiency in antibody optimization and reducing the time-to-market for its innovative pipeline. Investors will be closely monitoring the company's progress in expanding its clinical footprint and its ability to translate preclinical success into meaningful patient outcomes.
See full BioAtla company page
